HeartFlow Wants To Accelerate Adoption Of AI-Powered Heart Disease Test With $2.4Bn SPAC Deal
SPAC Longview Acquisition Corp. said it will take Heartflow public in a transaction that will provide the combined company with $400m in cash.
You may also be interested in...
The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.
Investors have been wary of LuminaraDX since its placement on NASDAQ, driving the share price down.
In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.